Kamada (NASDAQ:KMDA) has entered into a binding term sheet for a 12-year contract manufacturing agreement with an undisclosed partner to manufacture FDA approved and commercialized specialty hyper-immune globulin product.
The company expects to commence commercial manufacturing of the product in early 2023.
Based on the current market sales volume, the new product is estimated to add approx. $8M to $10M in annual revenues.
Kamada will continue to manufacture and sell KEDRAB as well as our other proprietary products.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.